Recent Alzheimer's drug disappointment illuminates pathway for progress against the disease

(Amplify Public Affairs) In a letter released today by UsAgainstAlzheimer's, Co-Founder and Chairman George Vradenburg said the negative clinical trial of a once-promising Alzheimer's drug, Solanezumab, which showed clinically insignificant ability to slow cognitive decline in Alzheimer's patients, should be viewed not as a failure, but as a development that 'provides valuable lessons and suggests a way forward in the fight against Alzheimer's.'

from EurekAlert! - Social and Behavioral Science http://ift.tt/2jcxaha